Compare Providers
Home › News › Pricing

Four pricing structures separate an advertised GLP-1 figure from what lands on your card

Released: ·Last reviewed: ·Methodology v4.1

Researched By
Medical Researcher · Western University of Health Sciences
Last medically reviewed: August 2, 2026 · This page is informational and does not constitute medical advice.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Membership fees outside the headline, dose tiers, introductory rates and prepay-only pricing. They stack, and all four are visible if you ask four questions.

An advertised monthly figure is frequently the medication at a starting dose, on a twelve-month prepay, excluding a membership fee. Each is disclosed somewhere. None is comparable to a flat all-in figure.

The dose tier matters most. Every published efficacy figure was collected at a maintenance dose, so a price quoted at a starting dose describes a point in treatment no trial measured an outcome at.

One question collapses all four: what is the all-in monthly total at a maintenance dose? Breakdown: the advertised price is not the price.

Filed by the Transparent Peptide research desk. Corrections: the corrections log.